The Medicare Advantage value-based insurance design model will be expanded come 2020 pushed by a group of bipartisan senators. The expansion will include substance use disorders, pushed by Sens. Bob Casey (D-Pa.), John Thune (R-S.D.) and Chuck Grassley, (R-Iowa) in a letter to CMS Administrator Seema Verma.
The model was launched by the CMS last year to improve quality healthcare access and Medicare Advantage enrollees with chronic conditions. The value-based model allows quality healthcare plans to vary which results in cost savings for the end consumer and offer supplemental benefits using some of the technology such as A.I discussed by us in an earlier post here!
The senators have further requested the CMS include naloxone and medication-assistanted treatment in the future with the hope being to increase evidence-based opioid treatments.
“Given the ongoing opioid epidemic, adding substance use disorders to the list of specified clinical conditions identified for the MA VBID model is not on. We urge you to draw on value-based insurance design concepts that promote access to high-value, evidence-based healthcare.”
Intermountain Healthcare & Anthem earlier this month launched an alternative payment model concept specifically to address addiction recovery that could be the first patient-centererd medical home model to do so. The 'Addiction Recovery Medical Home' model as healthcare data intelligence firm Leavitt Partners are naming it, is meant to provide patients with use disorder treatment options.